When was Rezolute founded?

Rezolute was founded in 2012 and raised its 1st funding round within a year of its incorporation.

Where is Rezolute located?

Rezolute is headquartered in Denver, United States.

Who is the current CEO of Rezolute?

Nevan Charles Elam of Rezolute. They have also founded 1 company.

How many employees does Rezolute have?

As of Jun 30, 2023, the latest employee count at Rezolute is 51.

Is Rezolute a funded company?

Rezolute is a funded company, having raised an undisclosed amount across 21 funding rounds to date. The company's 1st funding round was a $***** Post IPO round, raised on Aug 07, 2012.

When was the latest funding round of Rezolute?

Rezolute's latest funding was a $***** Post IPO round on Oct 09, 2020, with participation from 4 investors.

Where does Rezolute rank among its competitors?

Rezolute ranks 67th amongst 3749 active competitors, of which 1280 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Moderna, which secured $590M in Jan, 2025.

Who are the top competitors of Rezolute?

Rezolute's top competitors include Jazz Pharmaceuticals, Moderna and Alexion. Among them, Moderna secured the most recent funding round in January, 2025.

Rezolute - 2026 Company Profile, Team, Funding, Competitors & Financials

Company Details

Developing transformative therapies for rare diseases, focusing on hyperinsulinism (HI). The company is a late-stage biopharmaceutical company dedicated to addressing serious unmet needs in rare diseases. It is focused on significantly improving outcomes for individuals with hypoglycemia caused by hyperinsulinism (HI). Their antibody therapy, ersodetug, is designed to treat all forms of HI and has shown substantial benefit in clinical trials and real-world use for the treatment of congenital hyperinsulinism (cHI) and tumor HI. The company is committed to developing medicines and working with partners to fight hyperinsulinism in all its forms. They are enrolling Phase III sunRIZE trial in the study of congenital hyperinsulinism. The company is focused on drug development for patients with rare diseases in multiple therapeutic areas.

Website: rezolutebio.com
Social
Email ID: *****@rezolutebio.com
Phone Number: +1 **********
Part Of

Key Metrics

Founded Year

2012

Location

Denver, United States

Stage

Public

Latest Funding Round

Post IPO, Oct 09, 2020, $*****

Investors

BVF Partners & 9 more

Ranked

67^th among 3749 active competitors

Employee Count

51 as on Jun 30, 2023

Investment & Acquisitions

XOMA Corporation

Similar Companies

Alexion & 1309 more

Exit Details

Public

View Rezolute's full profile

Rezolute is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Rezolute, Inc. CIN: 27-3440894 , United States, Active	Dec 31, 2011	-	51 (As on Jun 30, 2023)	-

Rezolute got listed on May 08, 2012.

Click here to take a look at Rezolute's IPO in detail

Rezolute has raised funding over 21 rounds. Its first funding round was on Aug 07, 2012. Its latest funding round was a Post IPO round on Oct 09, 2020 for $*****. 4 investors participated in its latest round. Rezolute has 10 institutional investors.

Here is the list of recent funding rounds of Rezolute:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Oct 09, 2020	6382522	Post IPO	8017540	1813447	6434896	1907577
Jul 24, 2019	5105682	Post IPO	2800203	3306675	5155602	Handok & 1 more
Apr 03, 2018	2124575	Post IPO	1551671	4915622	4759476	BVF Partners

Access funding benchmarks and valuations. Sign up today!

View details of Rezolute's funding rounds and investors

The founders of Rezolute are Nevan Charles Elam and Hoyoung Huh. Nevan Charles Elam is the CEO of Rezolute.

Here are the details of Rezolute's key team members:

Nevan Charles Elam: Co-Founder & CEO of Rezolute and founder of 1 other company.
Contact Info: 1 email address
Hoyoung Huh: Co-Founder of Rezolute and founder of 1 other company.

View details of Rezolute's Founder profiles and Board Members

Rezolute's employee count trend

Rezolute has 51 employees as of Jun 23. The total employee count is 21.0% more than what it was in Jun 22. Here is Rezolute's employee count trend over the years:

Uncover Rezolute's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Rezolute include Jazz Pharmaceuticals, Moderna and Alexion. Here is the list of Top 10 competitors of Rezolute, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, Astrazeneca & 31 others	80/100
3rd	Alexion 1992, Zurich (Switzerland), Acquired	Developer of therapies for patients with devastating and rare diseases	$133M	Allen & Company, Permira & 9 others	79/100
4th	BridgeBio 2015, Palo Alto (United States), Acquired	Developer of therapeutics for the treatment of genetic diseases	$434M	Viking Global Investors, KKR & 20 others	77/100
5th	Sana Biotechnology 2018, Seattle (United States), Public	Developer of genetically engineered cell therapies for multiple disorders	$821M	Bezos Expeditions, F-Prime Capital & 17 others	75/100
6th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	74/100
7th	Juno Therapeutics 2013, Seattle (United States), Acquired	Global biopharmaceutical company discovering, developing, and delivering innovative medicines	$317M	BB Biotech, RA Capital Management & 14 others	74/100
8th	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, Wellington & 6 others	74/100
9th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Third Rock Ventures, Nextech Invest & 20 others	73/100
10th	Kronos Bio 2017, San Mateo (United States), Acquired	Developer of small molecule based therapeutics for cancer treatment	$271M	Omega Funds, Vida Ventures & 18 others	72/100
67th	Rezolute 2012, Denver (United States), Public	Developing transformative therapies for rare diseases, focusing on hyperinsulinism (HI)	-	BVF Partners, Citadel & 8 others	67/100